EAM
VRDN icon

Exome Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Exome Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-217,294
Closed -$2.93M – 85
2025
Q1 		$2.93M Buy
+217,294
New +$3.7M 2.6% 14
2024
Q4 		– Sell
-174,400
Closed -$3.97M – 80
2024
Q3 		$3.97M Buy
+174,400
New +$2.85M 2.68% 12

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Exome Asset Management's VRDN Position: Q2 2025 in Review

Exome Asset Management sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 217,294 shares — an estimated $2.93M sold.

Exome Asset Management first reported a position in VRDN in Q3 2024 and held it in 2 quarters. The position peaked at $3.97M in Q3 2024. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

  • Exome Asset Management reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exome Asset Management sold 217,294 Viridian Therapeutics shares in Q2 2025, an estimated $2.93M.
  • Exome Asset Management first reported a position in Viridian Therapeutics in Q3 2024 and held it in 2 quarters.
  • Exome Asset Management's Viridian Therapeutics position peaked at $3.97M in Q3 2024.
  • 170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on Exome Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.